Monograph Details
|
|
Musculoskeletal Disorders
> Arthritis/rheumatic disorders
|
|
RIDAURA |
| Manufacturer |
|
Prometheus Labs, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
DMARD (gold salt). |
| Generic Name |
|
Auranofin 3mg; caps. |
| Indications |
|
Active rheumatoid arthritis unresponsive to NSAIDs. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 6mg daily in 1–2 divided doses. If response inadequate after 6 months, may increase to 3mg 3 times daily. If still ineffective after 3 months, discontinue. |
| Contraindications |
|
History of gold-induced disorders. |
| Precautions |
|
Be fully familiar with chrysotherapy and this product's toxicity before use. Impaired renal or hepatic function. Inflammatory bowel disease. Rash. History of bone marrow depression. Monitor urine, blood, renal, liver function and for GI bleeding. Discontinue immediately if thrombocytopenia, proteinuria, or hematuria occurs. Pregnancy (Cat.C), nursing mothers: not recommended. |
| Adverse Reactions |
|
Bone marrow depression, proteinuria, hematuria, diarrhea, GI upset, ulcerative colitis, rash, pruritus, exfoliative dermatitis, stomatitis, conjunctivitis, proteinuria, nephrotic syndrome, cholestatic jaundice, gold bronchitis, pneumonitis, peripheral neuropathy. |
| How Supplied |
|
Caps—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
